# US 2013/0157947 A1 · Compounds for stem cell differentiation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157947 A1
- Document ID: US20130157947A1
- Status: Published application
- Kind: A1
- Application number: 13/428,647
- Filed: 2012-03-23
- Published: 2013-06-20
- Earliest claimed: 2008-09-17
- Assignees: Sanford-Burnham Medical Research Institute; Human BioMolecular Research Institute; ChemRegen, Inc.
- Inventors: MARK MERCOLA; John Cashman; Marion Lanier; Erik Willems; Dennis Schade
- Web page: https://patentgrep.com/patent/US20130157947A1

## CPC

- C07D 215/54: attached in position 3
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/1875: {Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor}
- C07D 215/20: Oxygen atoms
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C12N 5/0618: {Cells of the nervous system}
- C12N 5/0652: {Cells of skeletal and connective tissues; Mesenchyme}
- C12N 5/0655: {Chondrocytes; Cartilage}
- C12N 5/0657: {Cardiomyocytes; Heart cells}
- C12N 5/067: {Hepatocytes}
- C12N 5/0676: {Pancreatic cells}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Small molecule compounds and methods for stem cell differentiation are provided herein. An example of a class of compounds that may be used to practice the methods disclosed herein is represented by enantiomerically pure isomers of compounds of Formula I: or a chirally pure stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein R1, R2, R3, R4, R5, R5′, R6, R6′, R7, R7′ are as described herein.

## Claims

### Claim 1

A compound of Formula I:
or a chirally pure stereoisomer, pharmaceutically acceptable salt or solvate thereof,
wherein:
R1 is independently hydrogen (C1-C6)alkyl or a moiety forming a salt;
R2 is independently hydrogen or (C1-C6)alkyl;
R3 is independently OR8 or NR13R13′;
R4 is independently substituted or unsubstituted aryl, heteroalkyl, heterocycloalkyl, or heteroaryl substituted or unsubstituted pyridine, wherein phenyl or pyridine is optionally independently substituted with 1 to 3 R9 substituents;
R5, R5′, R6, R6′, R7, and R7′ are each independently hydrogen or (C1-C6)alkyl;
R8, R13, and R13′ are each independently hydrogen, (C1-C6)alkyl, (C3-C8)cycloalkyl, substituted or unsubstituted heterocyclyl, aryl, (C1-C6)alkylaryl, or (C1-C6)alkylNR10R10′;
each R9 is independently hydrogen, halogen, (C1-C6)alkyl, (C1-C6)alkoxy, cyclo(C1-C6)alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyridine, substituted or unsubstituted indolyl; substituted or unsubstituted pyrrolidinyl, or substituted or unsubstituted piperidinyl, wherein phenyl, pyridine, indolyl, pyrrolidinyl and piperidinyl are each optionally independently substituted with hydrogen, halogen, or (C1-C6)alkyl; and
R10 and R10′ are each independently hydrogen, (C1-C6)alkyl, aryl, or (C1-C6)alkylaryl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is hydrogen; R2 is hydrogen, CH3 or CH2CH3; R3 is OR8; R4 is substituted or unsubstituted phenyl; R8 is hydrogen, CH3, CH2CH3,
and each R9 is independently hydrogen, F, Cl, Br, or I.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R8 is CH3, CH2CH3,

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound of Formula I has Formula IB:
or a pharmaceutically acceptable salt or solvate thereof, wherein X is CH or N; p is an integer from 0 to 4; n is an integer from 0 to 5; and each R11 and R12 are each independently hydrogen, halogen, or (C1-C6)alkyl.

### Claim 5 (depends on 4)

The compound of claim 4, wherein X is CH; R1 is hydrogen; R2 is hydrogen, CH3or CH2CH3; R3 is OR8; R8 is CH3, CH2CH3,
and R11 and R12 are each independently hydrogen, F, Cl, Br, I, CH3 or CH2CH3.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R8 is CH3, CH2CH3,

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound of Formula I has Formula IC:
or a pharmaceutically acceptable salt thereof, wherein X is CH or N; p is an integer from 0 to 4; n is an integer from 0 to 3; and each R11 and R12 are each independently hydrogen, halogen, or (C1-C6)alkyl.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R1 is hydrogen; R2 is hydrogen, CH3 or CH2CH3; R3 is OR8; R8 is CH3, CH2CH3,
and each R11 and R12 are each independently hydrogen, F, Cl, Br, I, CH3 or CH2CH3.

### Claim 9 (depends on 8)

The compound of claim 8, wherein R8 is CH3, CH2CH3,

### Claim 10 (depends on 1)

The compound of Formula I of claim 1, having formula:

### Claim 11 (depends on 1)

The compound of claim 1, wherein the pharmaceutically acceptable salt is the salt of 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid (L), aspartic acid (L), benzenesulfonic acid, benzoic acid, camphoric acid (+), camphor-10-sulfonic acid (+), capric acid (decanoic acid), caproic acid (hexanoic acid), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid (D), gluconic acid (D), glucuronic acid (D), glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isobutyric acid, lactic acid (DL), lactobionic acid, lauric acid, maleic acid, malic acid (−L), malonic acid, mandelic acid (DL), methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid (−L), salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid (+L), thiocyanic acid, toluenesulfonic acid (p), or undecylenic acid.

### Claim 12 (depends on 1)

A method for producing differentiated cells from stem cells, comprising contacting the stem cell either ex vivo or in vivo with a compound of claim 1.

### Claim 13 (depends on 12)

The method of claim 12, wherein the contacting is from about 24 to 192 hours.

### Claim 14 (depends on 12)

The method of claim 12, wherein the contacting is from about 48 to 144 hours.

### Claim 15 (depends on 12)

The method of claim 12, wherein the differentiated cells are cardiomyocytes, hepatocytes, or islet cells, chondrocytes, bone or neural cells.

### Claim 16 (depends on 12)

The method of claim 12, further comprising contacting the stem cells with Activin A.

### Claim 17 (depends on 12)

The method of claim 12, wherein the stem cells differentiate to mesoderm.

### Claim 18 (depends on 12)

The method of claim 12, further comprising contacting the stem cells with a TGF-beta protein.

### Claim 19 (depends on 18)

The method of claim 18, wherein the TGF-beta protein is TGF-beta 1 or 2, or a member of the bone morphogenetic protein (BMP) family.

### Claim 20 (depends on 12)

The method of claim 12, wherein the stem cells are embryonic stem cells, induced pluripotent stem cells, or adult stem or progenitor cells.

### Claim 21 (depends on 12)

The method of claim 12, wherein the differentiated stem cells are produced by inhibition of TGFb, comprising contacting TGFb with a compound of structural Formula (I).

### Claim 22

A method for selectively inhibiting TGFb, comprising contacting TGFBR2 with a compound of structural Formula (I).

### Claim 23

A method for the treatment of a disease or disorder associated with TGF, comprising administering to a subject in need thereof an effective amount of a compound of structural Formula (I).

### Claim 24 (depends on 23)

The method of claim 23, wherein the disease or disorder is cancer, fibrosis, or vascular disease.
